[Effects of E. coli LPS on human platelet aggregation]

Platelet aggregation is a key process in hemostasis and thrombosis. Prior research has shown that platelet activation involves intracellular calcium and cyclic nucleotides. However, the specific effects of bacterial lipopolysaccharide on platelet behavior remain unclear. This gap motivated investigations into how LPS influences aggregation and calcium dynamics. No prior work had resolved whether LPS acts directly on platelet membranes or through secondary mediators. The role of calcium in LPS-induced aggregation is still debated. Existing studies focus on arachidonic acid pathways, but this paper explores alternative mechanisms. The current study aims to clarify whether LPS alters calcium influx and aggregation independently of cyclooxygenase activity.

This study sought to determine how E. coli LPS affects platelet aggregation and intracellular calcium levels. Researchers aimed to identify whether LPS influences aggregation through calcium or cyclic AMP pathways. They tested whether cyclooxygenase inhibition alters LPS effects. The goal was to distinguish between primary and secondary signaling mechanisms. The study also aimed to assess whether LPS-induced aggregation is mediated by calcium influx. Researchers wanted to clarify whether LPS acts on platelet membranes directly. The purpose included comparing aggregation in calcium-rich and calcium-free environments. This work aimed to provide insights into LPS-induced platelet behavior in inflammatory conditions.

The study used washed platelets from healthy volunteers. Platelet aggregation was measured using ADP as a stimulus. Intracellular calcium was monitored with the fluorescent indicator quin 2. Platelet suspensions were prepared in saline or citrated plasma. LPS was added to observe aggregation changes. Cyclooxygenase inhibitors were used to assess their effect. Dibutyryl cyclic AMP and verapamil were tested as antagonists. Calcium levels were compared in calcium-rich and calcium-free solutions.

LPS increased platelet aggregation in saline suspensions. In citrated plasma, LPS inhibited ADP-induced aggregation. Cyclooxygenase inhibitors had no significant effect on LPS outcomes. Dibutyryl cyclic AMP and verapamil partially reversed LPS effects. In calcium-rich suspensions, LPS raised intracellular calcium from 150 to 334 nM. In calcium-free suspensions, no significant calcium change occurred. These findings suggest LPS affects calcium influx. LPS-induced aggregation was not mediated by arachidonic acid derivatives.

The authors propose that LPS alters platelet membrane calcium influx. LPS increased intracellular calcium in calcium-rich environments. These changes were partially reversed by cyclic AMP and verapamil. Cyclooxygenase inhibition had no effect on LPS outcomes. The authors suggest LPS acts directly on platelet membranes. The study indicates calcium, not arachidonic acid, mediates LPS effects. LPS-induced aggregation may not be central to disseminated intravascular coagulation. The findings highlight alternative pathways for platelet activation.